Predicting CDK4/6 inhibitors outcomes in pts with HR+/HER2-metastatic breast cancer: A machine learning approach

被引：0
|
作者：
Moiso, Enrico [1 ]
Ferraro, Emanuela [1 ]
Cabel, Luc [1 ]
Safonov, Anton [1 ]
Ahmed, Mehnaj [1 ]
An, Julia Ah-Reum [1 ]
Jhaveri, Komal L. [1 ]
Norton, Larry [1 ]
Robson, Mark E. [1 ]
Modi, Shanu [1 ]
Chandarlapaty, Sarat [1 ]
Razavi, Pedram [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1074
引用
收藏
页数：1
相关论文
共 50 条
  • [1] HR+/HER2-metastatic Breast Cancer Increasing Data Density of CDK4/6 Inhibitors
    Freye, Reimund
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (09) : 485 - 485
  • [2] HEALTHCARE COSTS IN WOMEN WITH HR+/HER2-METASTATIC BREAST CANCER TREATED WITH CDK4/6 INHIBITORS
    Burne, R.
    Balu, S.
    Guerin, A.
    Liang, Y.
    Schloessmann, R.
    Bungay, R.
    Paul, M. L.
    VALUE IN HEALTH, 2020, 23 : S44 - S44
  • [3] Real-world experience with CDK4/6 inhibitors for HR+/HER2-metastatic breast cancer (MBC)
    Abdallah, H. M. A.
    Owoseni, Y. I.
    Sultan, A.
    Ahmed, S.
    Wood, J.
    Varadhan, B.
    Ayodele, O.
    ANNALS OF ONCOLOGY, 2023, 34 : S369 - S370
  • [4] Analyzing the changes in the HR+/HER2-metastatic breast cancer (mBC) landscape since the arrival of CDK4/6 inhibitors with machine learning and visual analytics
    Meade, D.
    Alford, S. Hensley
    Mahatma, S.
    Malangone-Monaco, E.
    Boulanger, L.
    Tkacz, J.
    Turner, S. J.
    Chen, S.
    Manson, S.
    Mejia, S.
    Buleje, I.
    Madan, P.
    Kim, G.
    Fowler, R.
    Basar, A.
    CANCER RESEARCH, 2019, 79 (04)
  • [5] Breast Cancer CDK4/6 Inhibitors in Patients with metastatic HR+/HER2-Breast Cancer
    Schmale, Ine
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 (1-2)
  • [6] How to Treat HR+/HER2-Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story
    Cogliati, Viola
    Capici, Serena
    Pepe, Francesca Fulvia
    di Mauro, Pierluigi
    Riva, Francesca
    Cicchiello, Federica
    Maggioni, Claudia
    Cordani, Nicoletta
    Cerrito, Maria Grazia
    Cazzaniga, Marina Elena
    LIFE-BASEL, 2022, 12 (03):
  • [7] Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2-metastatic breast cancer
    Zagami, Paola
    Esposito, Angela
    Salimbeni, Beatrice Taurelli
    Giachetti, Pier Paolo Maria Berton
    Scafetta, Roberta
    Lambertini, Matteo
    Di Maio, Massimo
    Curigliano, Giuseppe
    Criscitiello, Carmen
    Cinieri, Saverio
    BREAST, 2025, 79
  • [8] Approaching Use of CDK4/6 Inhibitors in Metastatic HR+, HER2-Breast Cancer
    Weiss, Jennifer
    Afghahi, Anosheh
    Shagisultanova, Elena
    Diamond, Jennifer R.
    ONCOLOGY-NEW YORK, 2018, 32 (10): : 513 - 515
  • [9] Social Determinants of Health and Other Predictors in Initiation of Treatment with CDK4/6 Inhibitors for HR+/HER2-Metastatic Breast Cancer
    Goyal, Ravi K.
    Candrilli, Sean D.
    Abughosh, Susan
    Chen, Hua
    Holmes, Holly M.
    Johnson, Michael L.
    CANCERS, 2024, 16 (12)
  • [10] Impact of CDK4/6 inhibitors on chemotherapy utilization in earlier therapy lines for HR+/HER2-metastatic breast cancer in the United States
    Goyal, Ravi K.
    Holmes, Holly M.
    Chen, Hua
    Abughosh, Susan
    Candrilli, Sean D.
    Johnson, Michael L.
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 198 (01) : 159 - 166
12345